FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
25 letters match. Newest first.
-
DrugsDabur India Limited
FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.
High risk -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
DrugsNew Life Pharma LLC
New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
High risk -
DrugsFlowchem Pharma Private Limited
FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.
High risk -
DrugsCohance Lifesciences Limited
Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.
High risk -
DrugsMedinatura New Mexico, Inc.
FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.
High risk -
DrugsApotex Inc.
FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.
High risk -
DrugsThe Tranzonic Companies/Innocore Sales & Marketing Inc.
FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.
High risk -
DrugsCreative Essences, Inc.
FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.
High risk -
DrugsDixon Investments Inc. dba ARI
FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.
High risk -
AnimalSynergy Animal Products, Inc.
Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.
High risk -
DrugsKabana Skin Care LLC
Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
High risk -
DrugsXtreme Tools International, Inc.
FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk -
DrugsArt of Beauty Company, Inc.
FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.
High risk -
DrugsSun Pharmaceutical Industries Limited
FDA cited Sun Pharmaceutical Industries for inadequate cleaning and maintenance at its Dadra drug plant, risking cross-contamination, and for weak investigations.
High risk -
DrugsSani-Care Salon Products, Inc.
FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.
High risk -
DrugsNatuzen Co., Ltd.
Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.
High risk -
DrugsKor-Chem, Inc.
Kor-Chem, Inc. made OTC hand sanitizer drugs with manufacturing violations, including shared equipment with industrial chemicals and missing identity and microbial testing.
High risk -
DrugsSafecor Health, LLC
FDA warned drug repackager Safecor Health over CGMP failures that let tablets from other drugs contaminate packaging lines.
High risk -
DrugsBaxter Healthcare Corporation
FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.
High risk -
DrugsCentaur Pharmaceuticals Private Ltd.
FDA warns Centaur Pharmaceuticals over manufacturing practice failures in active ingredients, including records and cleaning.
High risk -
DrugsAmerican Cleaning Solutions
FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.
High risk -
DrugsChameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation
FDA warned Chameleon Sanitizer Corporation that its hand sanitizer was made under insanitary conditions and violated manufacturing and misbranding rules.
High risk